

Molecular Imaging

REVIEW August | 2008

NEWS & PRESS

- ▶ Industry News
- ▶ Clinical News
- ▶ Regulatory News

LITERATURE

- ▶ PET Review
- ▶ SPECT Review
- ▶ Therapy Review

EDUCATION

- ▶ Presentations
- ▶ CME Courses

EVENTS

- ▶ Trade Shows
- ▶ Symposia

RESOURCES

- ▶ Meeting Abstracts
- ▶ Recent Books

MORE INFO

- ▶ Contacts
- ▶ Links

QUICK LINKS

INDUSTRY NEWS |

APOSENSE® [18F]-ML-10 to be Radiolabelled by IBA Molecular for Multi-Center Clinical Trials
August 13, 2008 iba-worldwide.com

Louvain-la-Neuve, Belgium and Petach-Tikva, Israel, August 13, 2008 -- IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) the leading global provider of PET radiopharmaceuticals, and NST (NeuroSurvival Technologies Ltd.) the leading developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced the signing of a collaboration agreement for radio-labeling and distributing APOSENSE® [18F]-ML-10, NST's novel agent for molecular imaging of apoptosis, to sites participating in multi-center clinical trials of APOSENSE® [18F]-ML-10. [Read more . . .](#)

LITERATURE REVIEW |

Clinical Implication and Prognostic Significance of Standardised Uptake Value of Primary Non-Small Cell Lung Cancer on PET: Analysis of 176 Cases
European Journal of Cardiothoracic Surgery. 2008 Aug 20

Objective: We sought to assess the clinical implication and prognostic significance of maximum standardised uptake value (SUV(max)) of primary non-small cell lung cancer (NSCLC) staged by integrated PET-CT. [Read More . . .](#)

EDUCATION |

IBA Molecular's Online Education Presentation: "PET & PET/CT for Breast Cancer," with Dr. Todd Blodgett, University of Pittsburgh Medical Center
Wednesday, October 15, 2008 3:00PM EDT

CLINICAL NEWS |

UnitedHealth Pushes Imaging Accreditation Deadline to 2009
August 22, 2008 AuntMinnie.com